Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis

Giovanni Palladini, Carlo Campana, Catherine Klersy, Alessandra Balduini, Giovanbattista Vadacca, Vittorio Perfetti, Stefano Perlini, Laura Obici, Edoardo Ascari, Gianvico Melzi D'Eril, Remigio Moratti, Giampaolo Merlini

Research output: Contribution to journalArticle


Background - Brain natriuretic peptide (BNP) is a marker of ventricular dysfunction and can be used to assess prognosis in heart failure and after myocardial infarction. Heart involvement is the most important prognostic factor and causes death in almost all patients with light-chain amyloidosis (AL). We investigated the prognostic value of NT-proBNP and its utility in monitoring amyloid heart dysfunction. Methods and Results - NT-proBNP was quantified at diagnosis in 152 consecutive patients seen at the coordinating center of the Italian Amyloidosis Study Group (Pavia) from 1999 throughout 2001. Heart involvement was estimated on the basis of clinical signs, electrocardiography, and echocardiography. NT-proBNP concentrations differed in patients with (n=90, 59%) and without (n=62, 41%) heart involvement (median: 507.8 pmol/L versus 22.1 pmol/L, P= 10-7). The best cutoff for heart involvement was at 152 pmol/L (sensitivity: 93.33%, specificity: 90.16%, accuracy: 92.05%) and distinguished two groups with different survival (P

Original languageEnglish
Pages (from-to)2440-2445
Number of pages6
Issue number19
Publication statusPublished - May 20 2003



  • Amyloid
  • Cardiomyopathy
  • Natriuretic peptides
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this